雷贝拉唑联合莫沙比利治疗胃食管反流病124例临床疗效观察

Effect of Rabeprazole Combined with Mosapride in Treating Patients with Gastroesophageal Reflux Disease

目的研究雷贝拉唑联合莫沙比利治疗胃食管反流病的临床疗效。方法将我院2010年7月至2012年1月收治的247例胃食管反流病患者随机分为观察组124例及对照组123例。在一般治疗及生活指导的基础上,观察组患者给予雷贝拉唑联合莫沙比利治疗,其中雷贝拉唑10mg/次,2次/d,莫沙比利5mg/d,3次/d;对照组患者给予奥美拉唑联合多潘立酮治疗,其中奥美拉唑20mg/次,2次/d,多潘立酮10mg/次,3次/d。所有患者均接受治疗8周。记录患者临床症状改善情况,分别于治疗前后于内镜下观察患者食管黏膜情况。结果两组患者接受治疗8周后临床症状评分均显著小于接受治疗前(P<0.01),且观察组患者治疗后症状评分(0.94±0.13)显著小于对照组患者(1.58±0.21),P<0.01。观察组患者治疗总有效率89.5%显著高于对照组73.2%(P<0.01)结论雷贝拉唑联合莫沙比利治疗胃食管反流病具有显著疗效,值得临床推广应用。

Objective To research the effect of rabeprazole combined with mosapride in treating patients with gastroesophageal reflux disease. Method From 2010 July to 2012 in January Divide 247 patents with gastroesophageal reflux disease into 2 groups. The 124 patients in observation group were treated with rabeprazole combined with mosapride while the 123 patients in control group were treated with omeprazole for 8 weeks. Record and compare the clinical symptom and efficacy under endoscopic. Results The clinical symptom score after treatment of the two groups were all significantly lower than before treatment while the score of the observation group after treatment was significantly lower than control group; the efficacy under endoscopic of the observation was 89.5%, significantly higher than control group 73.2% （P〈0.01）. Conclusion The clinical effect ofrabeprazole combined with mosapride is remarkable in treating gastroesophageal reflux disease.